Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Crespi, Gabriela A N ^a   Hermans, Stefan J ^a   Parker, Michael W ^a,b   Miles, Luke A ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CRENEZUMAB; DIPEPTIDE; MONOCLONAL ANTIBODY; SOLANEZUMAB;

ALZHEIMER DISEASE; BINDING SITE; BLOOD; CHEMISTRY; HUMAN; HYDROGEN BOND; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULAR DYNAMICS; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; HUMANS; HYDROGEN BONDING; IMMUNOTHERAPY; MOLECULAR DYNAMICS SIMULATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84928018961     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09649     Document Type: Article

References (37)

1. Herrmann, A. & Spires-Jones, T. Clearing the way for tau immunotherapy in Alzheimer's disease. J. Neurochem. 132, 1-4 (2015).
2. Hardy, J. et al. Pathways to Alzheimer's disease. J. Intern. Med. 275, 296-303 (2014).
3. Adolfsson, O. et al. An effector-reduced anti-b-amyloid (Ab) antibody with unique Ab binding properties promotes neuroprotection and glial engulfment of Ab. J. Neurosci. 32, 9677-9689 (2012).
4. Legleiter, J. et al. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335, 997-1006 (2004).
5. Choi, S. H. et al. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515, 274-278 (2014).
6. Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333 (2014).
7. Doody, R. S. et al. Phase 3 trials of solanezumab formild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321 (2014).
8. Villemagne, V. L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol. 12, 357-367 (2013).
9. Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 11, 657-660 (2012).
10. Shimada, H. The DIAN study. Brain Nerve 65, 1178-1184 (2013).
11. Reiman, E. M. et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26, 321-329 (2011).
12. Bales, K. R. et al.,inventors; Bales, K. R. et al.,assignees. Humanized antibodies that sequester amyloid beta peptide. World Intellectual Property Organization patent WO 2001062801 A2. 2001 August 30.
13. Watt, A. D. et al. Do current therapeutic anti-Abeta antibodies for Alzheimer's disease engage the target? Acta Neuropath. 127, 803-810 (2014).
14. Laskowski, R. A. & Swindells, M. B. LigPlot1:multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 51, 2778-2786 (2011).
15. Miles, L. A. et al. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J. Mol. Biol. 377, 181-192 (2008).
16. Gardberg, A. S. et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 104, 15659-15664 (2007).
17. Bohrmann, B. et al. Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28, 49-69 (2012).
18. Basi, G. S. et al. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 285, 3417-3427 (2010).
19. Wun, K. S. et al. Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease. Acta Crystallogr. F Struct. Biol. Commun. 64, 438-441 (2008).
20. Miles, L. A., Crespi, G. A., Doughty, L. & Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci. Rep. 3, 1302 doi:10.1038/srep01302 (2013).
21. Feinberg, H. et al. Crystal structure reveals conservation of amyloid-beta conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res. Ther. 6, 31 (2014).
22. Crespi, G. A., Ascher, D. B., Parker, M. W. & Miles, L. A. Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-b. Acta Crysta. Sect. F Struct. Biol. Commun. 70, 374-377 (2014).
23. La Porte, S. L. et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Biol. 421, 525-536 (2012).
24. Tomaselli, S., et al. The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 7, 257-267 (2006).
25. Poulsen, S. A., Watson, A. A., Fairlie, D. P. & Craik, D. J. Solution structures in aqueous SDSmicelles of two amyloid beta peptides ofAbeta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F). J. Struct. Biol. 130, 142-152 (2000).
26. Colletier, J. P. et al. Molecular basis for amyloid-beta polymorphism. Proc. Natl. Acad. Sci. USA. 108, 16938-16943 (2011).
27. Spencer, R. K., Li, H. & Nowick, J. S. X-ray crystallographic structures of trimers and higher-order oligomeric assemblies of a peptide derived from Ab(17-36). J. Am. Chem. Soc. 136, 5595-5598 (2014).
28. Moreth, J., Mavoungou, C. & Schindowski, K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun. Ageing. 10, 18-26 (2013).
29. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
30. Raghunathan, G., Smart, J., Williams, J. & Almagro, J. C. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J. Mol. Recognit. 25, 103-113 (2012).
31. World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 100. WHO Drug Information 22, 311-367 (2008).
32. Harris, L. J., Skaletsky, E. & McPherson, A. Crystallization of intact monoclonal antibodies. Proteins 23, 285-289 (1995).
33. McPhillips, T. M. et al. Blu-Ice and the Distributed Control System: Software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 9, 401-406 (2002).
34. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
35. Collaborative Computational Project, Number 4 The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
36. Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
37. Davis, I. W.,Murray, L. W., Richardson, J. S. & Richardson, D. C. MOLPROBITY: Structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32 (Web Server issue)W615-619 doi:10.1093/nar/gkh398 (2004).